JAGSNPHARM.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine...

Stats
Šios dienos apimtis	80 320.00
Vidutinė apimtis	46 439.00
Rinkos kapitalizacija	9.05B
EPS	INR0 ( 2024-02-02 )
Kita pelno data	( INR0 ) 2024-05-20
Last Dividend	INR5.00 ( 2023-08-21 )
Next Dividend	INR0 ( N/A )
P/E	37.02
ATR14	INR0.457 (0.13%)

Tūris Koreliacija

Ilgas: 0.22 (neutral)

Trumpas: 0.36 (neutral)

Signal:(62.288) Neutral

Jagsonpal Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
20MICRONS.NS	0.912
MUTHOOTFIN.NS	0.91
21STCENMGM.NS	0.902
DELPHIFX.NS	0.889
STAR.NS	0.887
ICICIPHARM.NS	0.887
KCP.NS	0.879
MEDICAMEQ.NS	0.877
IGPL.NS	0.876
PVP.NS	0.873

10 Labiausiai neigiamai susiję koreliacijos
RAJRILTD.NS	-0.926
4THDIM.NS	-0.912
LTGILTBEES.NS	-0.876
SYMPHONY.NS	-0.869
SRTRANSFIN.NS	-0.84
ISMTLTD.NS	-0.833
GNA.NS	-0.832
SHRIRAMEPC.NS	-0.807
JSL.NS	-0.801

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Jagsonpal Pharmaceuticals Koreliacija - Valiuta/Žaliavos

-0.37
( neutral )

-0.21
( neutral )

-0.56
( weak negative )

0.21
( neutral )

-0.21
( neutral )

0.57
( weak )

Jagsonpal Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	INR2.37B
Bruto pelnas:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Pajamos:	INR2.37B
Bruto pelnas:	INR1.44B (60.67 %)
EPS:	INR10.20

FY	2022
Pajamos:	INR2.26B
Bruto pelnas:	INR1.30B (57.49 %)
EPS:	INR7.48

FY	2021
Pajamos:	INR1.88B
Bruto pelnas:	INR1.07B (56.92 %)
EPS:	INR6.51

Financial Reports:

No articles found.

Jagsonpal Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR5.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Jagsonpal Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.51 - low (49.85%) | Divividend Growth Potential Score: 5.55 - Stable (10.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.75	2003-05-30
Last Dividend	INR5.00	2023-08-21
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR19.95	--
Avg. Dividend % Per Year	1.32%	--
Score	2.75	--
Div. Sustainability Score	4.51
Div.Growth Potential Score	5.55
Div. Directional Score	5.03	--

Next Divdend (Est)
(2024-07-05)

INR5.77 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.75

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.100	0.36%
2019	INR0.250	0.79%
2020	INR0.500	1.95%
2021	INR5.00	6.21%
2022	INR0	0.00%
2023	INR5.00	1.36%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SARDAEN.NS	Dividend Junior	2023-09-07	Annually	15	0.65%
MAGADSUGAR.NS	Dividend Junior	2023-07-13	Annually	7	1.78%
GMDCLTD.NS	Dividend Knight	2023-09-22	Annually	23	3.41%
ASTRAMICRO.NS	Dividend Junior	2023-08-23	Annually	20	0.49%
TITAN.NS	Dividend Junior	2023-07-13	Annually	20	0.35%
PETRONET.NS	Dividend Knight	2023-08-18	Semi-Annually	18	2.36%
JASH.NS	Dividend Junior	2023-09-22	Annually	7	0.57%
DBOL.NS	Dividend Junior	2023-06-23	Insufficient data to determine frequency	2	0.56%
SILINV.NS	Dividend Junior	2023-08-18	Annually	23	0.63%
MBAPL.NS	Dividend Junior	2023-09-18	Annually	8	0.44%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.111	1.500	7.78	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	39.98	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.34	2.00	7.33	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.609	1.000	3.19	3.19	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.13	9.13	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	36.84	1.000	6.38	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
dividendYielPercentageTTM	1.455	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.34	2.00	8.22	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	3.48	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0636	1.000	-0.909	0	[0.1 - 0.5]
Total Score				5.55

Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.